Advanced search
1 file | 309.87 KB Add to list

Endothelial cell-specific molecule-1 in critically ill patients with hematologic malignancy

(2018) CRITICAL CARE MEDICINE. 46(3). p.e250-e257
Author
Organization
Abstract
Objectives: To assess whether serum concentration of endothelial cell-specific molecule-1 (Endocan) at ICU admission is associated with the use of ICU resources and outcomes in critically ill hematology patients. Design: Prospective multicenter cohort study. Setting: Seventeen ICUs in France and Belgium. Patients: Seven hundred forty-four consecutive critically ill hematology patients; 72 critically ill septic patients without hematologic malignancy; 276 healthy subjects. Intervention: None. Measurements and Main Results: Median total endocan concentrations were 4.46 (2.7-7.8) ng/mL. Endocan concentrations were higher in patients who had received chemotherapy before ICU admission (4.7 [2.8-8.1] ng/mL vs. 3.7 [2.5-6.3] ng/mL [p = 0.002]). In patients with acute respiratory failure, endocan levels were increased in patients with drug-induced pulmonary toxicity compared with other etiologies (p = 0.038). Total endocan levels higher than 4.46ng/mL were associated with a higher cumulative probability of renal replacement therapy requirement (p = 0.006), a higher requirement of mechanical ventilation (p = 0.01) and a higher requirement of vasopressors throughout ICU stay (p < 0.0001). By multivariate analysis, total endocan levels at admission were independently associated with ICU mortality (odds ratios, 1.39; 95% CI, 1.06-1.83; p = 0.018). The predictive value of endocan peptide fragments of 14kDa in terms of mortality and life-sustaining therapies requirement was inferior to that of total endocan. Endocan levels were higher in critically ill hematology patients compared with healthy subjects (p < 0.0001) but lower than endocan values in critically ill septic patients without hematologic malignancy (p = 0.005) Conclusions: Serum concentrations of endocan at admission are associated with the use of ICU resources and mortality in critically ill hematology patients. Studies to risk-stratify patients in the emergency department or in the hematology wards based on endocan concentrations to identify those likely to benefit from early ICU management are warranted.
Keywords
chemotherapy, endocan, endothelium, hematologic malignancy, intensive care unit, ACUTE MYELOID-LEUKEMIA, ENDOCAN, SEPSIS, BIOMARKER, FAILURE, MARKER, TARGET, CANCER, ESM-1

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 309.87 KB

Citation

Please use this url to cite or link to this publication:

MLA
Zafrani, Lara, Matthieu Resche-Rigon, Nathalie De Freitas Caires, et al. “Endothelial Cell-specific Molecule-1 in Critically Ill Patients with Hematologic Malignancy.” CRITICAL CARE MEDICINE 46.3 (2018): e250–e257. Print.
APA
Zafrani, L., Resche-Rigon, M., De Freitas Caires, N., Gaudet, A., Mathieu, D., Parmentier-decrucq, E., Lemiale, V., et al. (2018). Endothelial cell-specific molecule-1 in critically ill patients with hematologic malignancy. CRITICAL CARE MEDICINE, 46(3), e250–e257.
Chicago author-date
Zafrani, Lara, Matthieu Resche-Rigon, Nathalie De Freitas Caires, Alexandre Gaudet, Daniel Mathieu, Erika Parmentier-decrucq, Virginie Lemiale, et al. 2018. “Endothelial Cell-specific Molecule-1 in Critically Ill Patients with Hematologic Malignancy.” Critical Care Medicine 46 (3): e250–e257.
Chicago author-date (all authors)
Zafrani, Lara, Matthieu Resche-Rigon, Nathalie De Freitas Caires, Alexandre Gaudet, Daniel Mathieu, Erika Parmentier-decrucq, Virginie Lemiale, Djamel Mokart, Frédéric Pène, Achille Kouatchet, Julien Mayaux, François Vincent, Martine N’yunga, Fabrice Bruneel, Antoine Rabbat, Christine Lebert, Pierre Perez, Anne-Pascale Meert, Dominique Benoit, Michael Darmon, and Elie Azoulay. 2018. “Endothelial Cell-specific Molecule-1 in Critically Ill Patients with Hematologic Malignancy.” Critical Care Medicine 46 (3): e250–e257.
Vancouver
1.
Zafrani L, Resche-Rigon M, De Freitas Caires N, Gaudet A, Mathieu D, Parmentier-decrucq E, et al. Endothelial cell-specific molecule-1 in critically ill patients with hematologic malignancy. CRITICAL CARE MEDICINE. 2018;46(3):e250–e257.
IEEE
[1]
L. Zafrani et al., “Endothelial cell-specific molecule-1 in critically ill patients with hematologic malignancy,” CRITICAL CARE MEDICINE, vol. 46, no. 3, pp. e250–e257, 2018.
@article{8585851,
  abstract     = {Objectives: To assess whether serum concentration of endothelial cell-specific molecule-1 (Endocan) at ICU admission is associated with the use of ICU resources and outcomes in critically ill hematology patients. 
Design: Prospective multicenter cohort study. 
Setting: Seventeen ICUs in France and Belgium. 
Patients: Seven hundred forty-four consecutive critically ill hematology patients; 72 critically ill septic patients without hematologic malignancy; 276 healthy subjects. 
Intervention: None. 
Measurements and Main Results: Median total endocan concentrations were 4.46 (2.7-7.8) ng/mL. Endocan concentrations were higher in patients who had received chemotherapy before ICU admission (4.7 [2.8-8.1] ng/mL vs. 3.7 [2.5-6.3] ng/mL [p = 0.002]). In patients with acute respiratory failure, endocan levels were increased in patients with drug-induced pulmonary toxicity compared with other etiologies (p = 0.038). Total endocan levels higher than 4.46ng/mL were associated with a higher cumulative probability of renal replacement therapy requirement (p = 0.006), a higher requirement of mechanical ventilation (p = 0.01) and a higher requirement of vasopressors throughout ICU stay (p < 0.0001). By multivariate analysis, total endocan levels at admission were independently associated with ICU mortality (odds ratios, 1.39; 95% CI, 1.06-1.83; p = 0.018). The predictive value of endocan peptide fragments of 14kDa in terms of mortality and life-sustaining therapies requirement was inferior to that of total endocan. Endocan levels were higher in critically ill hematology patients compared with healthy subjects (p < 0.0001) but lower than endocan values in critically ill septic patients without hematologic malignancy (p = 0.005) 
Conclusions: Serum concentrations of endocan at admission are associated with the use of ICU resources and mortality in critically ill hematology patients. Studies to risk-stratify patients in the emergency department or in the hematology wards based on endocan concentrations to identify those likely to benefit from early ICU management are warranted.},
  author       = {Zafrani, Lara and Resche-Rigon, Matthieu and De Freitas Caires, Nathalie and Gaudet, Alexandre and Mathieu, Daniel and Parmentier-decrucq, Erika and Lemiale, Virginie and Mokart, Djamel and Pène, Frédéric and Kouatchet, Achille and Mayaux, Julien and Vincent, François and N’yunga, Martine and Bruneel, Fabrice and Rabbat, Antoine and Lebert, Christine and Perez, Pierre and Meert, Anne-Pascale and Benoit, Dominique and Darmon, Michael and Azoulay, Elie},
  issn         = {0090-3493},
  journal      = {CRITICAL CARE MEDICINE},
  keywords     = {chemotherapy,endocan,endothelium,hematologic malignancy,intensive care unit,ACUTE MYELOID-LEUKEMIA,ENDOCAN,SEPSIS,BIOMARKER,FAILURE,MARKER,TARGET,CANCER,ESM-1},
  language     = {eng},
  number       = {3},
  pages        = {e250--e257},
  title        = {Endothelial cell-specific molecule-1 in critically ill patients with hematologic malignancy},
  url          = {http://dx.doi.org/10.1097/ccm.0000000000002934},
  volume       = {46},
  year         = {2018},
}

Altmetric
View in Altmetric
Web of Science
Times cited: